NCT02764333.

Trial name or title	A phase II trial of TPIV200/huFR‐1 (a multi‐epitope anti‐folate receptor vaccine) plus anti‐PD‐L1 MEDI4736 (durvalumab) in patients with platinum‐resistant ovarian cancer
Methods	Uncontrolled phase II
Participants	40 participants with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
Interventions	Intradermal TPIV200 (vaccine targeting folate receptor alpha mixed with GM‐CSF) and intravenous durvalumab
Outcomes	Clinical response
Starting date	May 2016
Contact information
Notes	Active not recruiting, March 2018